omalizumab

July 12, 2016July 12, 2016

FDA Approves Xolair for Allergic Pediatric Asthma

Asthma, News

Genentech recently announced that the U.S. Food and Drug Administration (FDA) approved Xolair (omalizumab) for the treatment of persistent allergic asthma in children aged 6 to 11 years old. Xolair therapy was already ... Read more

March 16, 2016March 16, 2016

People with Severe Asthma Are Focus of Study to Better Target Treatment of XolairR

Asthma, News

A new study developed by researchers at the National Institute for Health Research (NIHR) Southampton Respiratory Biomedical Research Unit in England and managed by the NIHR-funded Clinical Trials Unit at the University of ... Read more

March 4, 2016March 4, 2016

Genentech’s Application of Xolair for Allergic Asthma in Kids Is Under FDA Review

Asthma, News

Genentech recently announced that its supplemental Biologics License Application (sBLA) for extension of Xolair (omalizumab) in allergic asthma in pediatric patients has been accepted by the U.S. Food and Drug Administration (FDA). ... Read more

January 19, 2016

Study’s Focus on Fall Asthma Outbreaks Looks Promising for Children, Teens

Asthma, News

A newly released study has important clinical implications for the prevention and reduction of autumn asthma exacerbations in children. The study, “Preseasonal treatment with either omalizumab or an inhaled corticosteroid boost ... Read more

November 30, 2015November 30, 2015

Mid-summer Asthma Treatment May Help Prevent Fall Flare-ups

Asthma, News

A study shows that omalizumab (Xolair®, Genentech, Novartis) used in combination with standard care four to six weeks before the start of the school year helps to prevent asthma exacerbations in inner-city children and ... Read more

July 13, 2015November 6, 2015

Study Tests Effectiveness of Omalizumab in Treating Perennial Severe Allergic Asthma

Asthma, News

A new study exploring perennial severe allergic asthma entitled “Prevalence of perennial severe allergic asthma in Italy and effectiveness of omalizumab in its management: PROXIMA – an observational, 2 phase, patient ... Read more

October 21, 2014November 11, 2015

Four New Drugs for Respiratory Diseases Receive Public Funding in New Zealand

COPD, News

The New Zealand Crown health agency, Pharmaceutical Management Agency (PHARMAC), has announced that funding four new medications tailored for the treatment of respiratory diseases, which may help more than 10,000 people ... Read more

September 30, 2014November 6, 2015

FDA Includes Heart and Brain Problems to Asthma Drug Xolair’s Potential Risks

Asthma, News

The U.S. Food and Drug Administration (FDA) recently reviewed its drug safety recommendations, suggesting an increase in the risk of heart and blood problems as a result of the use of Xolair ... Read more